ObjectiveDevelopment of white matter hyperintensities (WMH) in the brain is associated with blood thrombogenicity in recently menopausal women. This study examined the influence of menopausal hormone treatments (MHTs) on this association.
MethodsMeasures of blood thrombogenicity were examined in women of the Kronos Early Estrogen Prevention Study (n?=?95) who had brain magnetic resonance imaging before and during the 48 months of randomization to transdermal 17?-estradiol (n?=?30), oral conjugated equine estrogen (n?=?29) both with progesterone for 12 days per month or placebo pills and patch (n?=?36). Principal components (PCs) analysis was used to reduce the dimensionality of 14 markers of platelet activation and blood thrombogenicity. The first 5 PCs were assessed for association with treatment and changes in WMH. Within-person slopes were obtained to capture the extent of WMH change for each woman.
ResultsWMH increased in all groups over the 48 months (P?=?0.044). The partial effect of PC1, representing an average of six thrombogenicity variables (microvesicles derived from endothelium, leukocytes, and monocytes, and positive for tissue factor and adhesion molecules) on WMH was significant (P?=?0.003). PC3, reflecting a contrast of platelet microaggregates and adenosine triphosphate secretion versus total platelet count, differed across groups (P?=?0.006) with higher scores in the oral conjugated equine estrogen group. The global association between PCs and WMH increase, however, did not differ significantly by MHT (P?=?0.207 for interaction between MHT and PC's).
ConclusionIn recently menopausal women, the type of MHT did not significantly influence the association of markers of blood thrombogenicity with development of WMH in the brain.
SUBMITTER: Jayachandran M